Ge Long Hui A P P·2025-10-21 06:11Core Viewpoint - The A-share market is experiencing a surge in flu-related stocks, driven by rising flu activity in southern provinces and the emergence of the H3N2 strain, which has led to increased investor interest in pharmaceutical companies [1][2] Company Performance - Jinshi Yiyao: Increased by 13.44%, with a total market value of 4.644 billion [2] - Guangji Pharmaceutical: Rose by 9.97%, total market value of 2.448 billion [2] - Te Yi Pharmaceutical: Gained 8.78%, market value of 5.209 billion [2] - Hualan Biological Engineering: Up by 8.59%, with a market value of 12.9 billion [2] - Lingkang Pharmaceutical: Increased by 7.01%, market value of 4.291 billion [2] - Hengdi Pharmaceutical: Rose by 6.60%, market value of 5.466 billion [2] - Innotec: Increased by 5.37%, market value of 4.459 billion [2] - Weikang Pharmaceutical: Up by 4.76%, market value of 3.471 billion [2] - Yirui Biological: Increased by 4.67%, market value of 4.359 billion [2] Market Trends - The China CDC reported a slow increase in respiratory disease cases nationwide, with flu activity rising in southern provinces and remaining low in northern regions [1] - Experts suggest that the flu season may arrive earlier this year, with a potential increase in infection rates due to lower immunity against the H3N2 strain [1]